Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 19438394.
- Also identified by DOI 10.1086/599225.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The incidence of acute renal failure, defined by the risk, injury, or failure criteria of the RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease), in 66 patients who received colistimethate sodium was 45%, and 21% of patients stopped therapy because of nephrotoxicity. The RIFLE criteria should be used in the future to allow for comparison of nephrotoxicity among studies.
Medical subject headings
- Anti-Bacterial Agents
- Colistin
- Renal Insufficiency